Michael G. Ison, MD MS
@michaelisonmd.bsky.social
Transplant Infectious Diseases MD, clinical respiratory virologist and Editor-in-Chief of @TheTxIDJournal.bsky.social.
All opinions and tweets are my own.
All opinions and tweets are my own.
Important Ongoing Studies where we have or will have publications soon:
Pritelivir for refractory or resistant HSV (presented @idweek.bsky.social by @kottonnelson.bsky.social): www.aicuris.com/press-releas...
CD388 for prevention of influenza: www.cidara.com/news/cidara-...
Pritelivir for refractory or resistant HSV (presented @idweek.bsky.social by @kottonnelson.bsky.social): www.aicuris.com/press-releas...
CD388 for prevention of influenza: www.cidara.com/news/cidara-...
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Herpes Simplex Virus-infected Patients in Phase 3 Pivotal Trial - Aicuris
Aicuris today announced that the Phase 3 trial of its lead candidate pritelivir has met its primary and secondary endpoint. The aim of the trail was to evaluate
www.aicuris.com
October 22, 2025 at 1:40 PM
Important Ongoing Studies where we have or will have publications soon:
Pritelivir for refractory or resistant HSV (presented @idweek.bsky.social by @kottonnelson.bsky.social): www.aicuris.com/press-releas...
CD388 for prevention of influenza: www.cidara.com/news/cidara-...
Pritelivir for refractory or resistant HSV (presented @idweek.bsky.social by @kottonnelson.bsky.social): www.aicuris.com/press-releas...
CD388 for prevention of influenza: www.cidara.com/news/cidara-...
Results from season 3 of the GSK RSV Vaccine (NOTE - I was the lead author so I’m biased on this one)
www.thelancet.com/journals/lan...
Two trials on tecovirimat for Mpox and the need to consider research in context of EUA medications
www.nejm.org/doi/full/10....
evidence.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
Two trials on tecovirimat for Mpox and the need to consider research in context of EUA medications
www.nejm.org/doi/full/10....
evidence.nejm.org/doi/full/10....
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSV...
A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons
in people aged 60 years or older, despite a decrease in efficacy over time. Further
research is needed to establish th...
www.thelancet.com
October 22, 2025 at 1:39 PM
Results from season 3 of the GSK RSV Vaccine (NOTE - I was the lead author so I’m biased on this one)
www.thelancet.com/journals/lan...
Two trials on tecovirimat for Mpox and the need to consider research in context of EUA medications
www.nejm.org/doi/full/10....
evidence.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
Two trials on tecovirimat for Mpox and the need to consider research in context of EUA medications
www.nejm.org/doi/full/10....
evidence.nejm.org/doi/full/10....
Study of baloxavir to prevent household transmission of influenza
www.nejm.org/doi/full/10....
Two studies of monoclonals for RSV prevention
www.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
www.nejm.org/doi/full/10....
Two studies of monoclonals for RSV prevention
www.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza | NEJM
Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient...
www.nejm.org
October 22, 2025 at 1:38 PM
Study of baloxavir to prevent household transmission of influenza
www.nejm.org/doi/full/10....
Two studies of monoclonals for RSV prevention
www.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
www.nejm.org/doi/full/10....
Two studies of monoclonals for RSV prevention
www.nejm.org/doi/full/10....
www.thelancet.com/journals/lan...
Two trials on lenacapravir for prevention of HIV
www.nejm.org/doi/full/10....
www.nejm.org/doi/10.1056/...
Two trials on high dose influenza vaccine
jamanetwork.com/journals/jam...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/full/10....
www.nejm.org/doi/10.1056/...
Two trials on high dose influenza vaccine
jamanetwork.com/journals/jam...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/abs/10.1...
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure...
www.nejm.org
October 22, 2025 at 1:37 PM
Two trials on lenacapravir for prevention of HIV
www.nejm.org/doi/full/10....
www.nejm.org/doi/10.1056/...
Two trials on high dose influenza vaccine
jamanetwork.com/journals/jam...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/full/10....
www.nejm.org/doi/10.1056/...
Two trials on high dose influenza vaccine
jamanetwork.com/journals/jam...
www.nejm.org/doi/abs/10.1...
www.nejm.org/doi/abs/10.1...
Included in the supplement is an important paper about application of antivirals in immunocompromised patients @mady247.bsky.social
academic.oup.com/jid/article/...
academic.oup.com/jid/article/...
Influenza Antivirals for Prevention and Treatment in Immunocompromised People
Antivirals are an important backbone for the prevention and treatment of influenza in immunocompromised individuals, who are prone to prolonged viral shedd
academic.oup.com
October 20, 2025 at 6:27 PM
Included in the supplement is an important paper about application of antivirals in immunocompromised patients @mady247.bsky.social
academic.oup.com/jid/article/...
academic.oup.com/jid/article/...
Likewise, screening for FQ resistance may inform what breakthrough infections will occur and optimize early management.
May 14, 2025 at 4:14 PM
Likewise, screening for FQ resistance may inform what breakthrough infections will occur and optimize early management.
The future may be using the tool to look at pathogen and host response in the same assay - multiple examples shown that the combined approach provided answers that wouldn’t have been identified.
May 13, 2025 at 4:13 PM
The future may be using the tool to look at pathogen and host response in the same assay - multiple examples shown that the combined approach provided answers that wouldn’t have been identified.